Work

A phase Ib study of prexasertib, a checkpoint kinase (CHK1) inhibitor, and LY3023414, a dual inhibitor of class I phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) in patients with advanced solid tumors.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.3091

Authors: David S. Hong, Kathleen N. Moore, Johanna C. Bendell, Daniel D. Karp, Judy Sing-Zan Wang, Susanna Varkey Ulahannan, Melissa Lynne Johnson, Raid Aljumaily, Scott Hynes, Sophie Callies, Rodney Decker, Elizabeth LaBell, Michele Niland, Xuejing Aimee Wang, Aimee Bence Lin, Manish R. Patel

Institutions: The University of Texas MD Anderson Cancer Center, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, University of Oklahoma, Sarah Cannon, Tennessee Oncology, Florida Cancer Specialists & Research Institute, Eli Lilly (United States)

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2947348562

Cites:

Cited by: 4

Related to: 10